The United States Food and Drug Administration has granted Galderma’s nemolizumab a Breakthrough Therapy Designation following phase 2 results which suggests the drug is a considerable alleviant for pruritus associated with prurigo nodularis.
Collaboration between Leo Pharma and Portal Instruments brings needleless drug delivery device to forefront of dermatology industry
Leo Pharma A/S and Portal Instruments are now collaborating on a new needle-free handheld jet injector for patients that self-administer medicines for cutaneous diseases and ailments.
Patients on powerful immunocompromising agents might be predisposed to infections; however the potential association between biologic agents and increased risk isn’t necessarily universal, Whitney High, M.D., reported during the summer meeting of the American Academy of Dermatology.
Why do biologics lose efficacy over time? This physician discusses factors dermatologists should consider when they see this issue in their patients.
Biologic tildrakizumab-asmn approved with suffix as differentiator from future biosimilar versions.
The TNF alpha inhibitor certolizumab pegol (Cimzia, UCB) has achieved the highest response rates seen in phase three trials of self-injectable biologics for psoriasis.
Severe case of dupilumab-associated conjunctivitis successfully managed without discontinuing therapy.
Symptomatic relief remains out of reach for many who suffer chronic pruritis. Without drugs specifically approved to treat chronic itch, providers and patients rely on therapies with limited efficacy. Here’s an update of two important clinical trials.
Physicians may want to reconsider goals for the treatment of plaque psoriasis. In this study, physicians describe utilizing treat-to-target with a patient-centered approach to care for symptom relief.
As the list of treatments for plaque psoriasis grows, so does the list of adverse events associated with biologic treatment. In this article, we summarize adverse events associated with common treatments for plaque psoriasis.